Seagen Reports Fourth Quarter and Full Year 2022 Financial R

-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion--TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer--ADCETRIS Received Pediatric Indication with FDA Approval for Children wit...

Related Keywords

Georgetown University , District Of Columbia , United States , California , Canada , Russia , Washington , Switzerland , Seattle , Ukraine , Russian , American , David Caouette , Sandra Swain , Roger Dansey , Douglas Maffei , David Epstein , Additional International Launches For Current , Society For Immunotherapy Of Cancer , Zai Lab , Seagen Inc , Nasdaq , Novartis , Exchange Commission , Genetic Medicine For Medstar Health , Development Rd Expenses , Dean For Research Development , Novartis Pharmaceuticals , Corporate Communications , European Union , Company Quarterly Report On Form , National Comprehensive Cancer Network , Total Revenues , Annual Increase , Total Net Product Sales , Previously Treated , Positive Metastatic Colorectal , Pediatric Indication , Previously Untreated High Risk Hodgkin , Multiple Key Milestones Anticipated , Potential Label Expansion , Key Data Readouts , Additional International Launches , Conference Call Today , Chief Executive Officer , Supplemental Biologics License Application , First Line Advanced , Metastatic Urothelial Cancer , Priority Review , Global Phase , First Line Advanced Urothelial Cancer , New Data , American Society , Clinical Oncology Genitourinary Cancers , Positive Metastatic Colorectal Cancer , Previously Untreated High Risk Hodgkin Lymphoma , Preferred Regimen , National Comprehensive Cancer , Clinical Practice Guidelines , Cervical Cancer , Novel Antibody Drug Conjugate , Annual Meeting , Clinical Trial , Novel Bispecific Antibody Anticalin Candidate , Chief Medical Officer , Associate Dean , Research Development , Georgetown University Medical Center , Vice President , Genetic Medicine , Conquer Cancer Foundation Board , Clinical Oncology , Women Who Conquer Cancer , License Agreement , Product Sales , License Agreement Revenues , Products Sales , Quarterly Report , Consolidated Statements , Months Ended December , Ended December , Investor Relations ,